Case Report|Articles in Press

Sudden-onset gallbladder rupture due to Ceftriaxone-associated pseudolithiasis in a patient with acquired hemophilia A

Published:April 18, 2023DOI:


      We herein report a 76-year-old man with acquired hemophilia A (AHA) who developed gallbladder rupture due to Ceftriaxone (CTRX)-associated pseudolithiasis. The patient was admitted for an examination of systemic subcutaneous bleeding. A blood test showed a prolonged activated partial thromboplastin time and sequentially revealed low factor VIII activity (<1%) and a high factor VIII inhibitor level of 143 BU/mL. The patient was thus diagnosed with AHA. After admission, he developed a high-grade fever and was administered intravenous CTRX, considering the possibility of psoas abscess or cellulitis. Although his high-grade fever was improved, computed tomography incidentally showed a high-density lesion in the gallbladder, suggestive of CTRX-associated pseudolithiasis without clinical symptoms. Despite cessation of CTRX, the pseudolithiasis never disappeared, and the patient suddenly died after rapid progression of abdominal bloating. An autopsy revealed that the gallbladder was severely swollen and had ruptured with hemorrhaging because of hemorrhagic cholecystitis, caused by CTRX-associated pseudolithiasis with AHA. Our case demonstrated that CTRX-associated pseudocholelithiasis can unexpectedly induce gallbladder hemorrhaging and rupture in a patient with a bleeding diathesis, including AHA. CTRX-associated pseudocholelithiasis can cause a fatal outcome in patients with a bleeding disorder, even if CTRX is ceased as soon as pseudocholelithiasis is detected.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Menegatti M.
        • Biguzzi E.
        • Peyvandi F.
        Management of rare acquired bleeding disorders.
        Hematol. Am. Soc. Hematol. Educ. Progr. 2019; 2019: 80-87
        • Ma Z.
        • Xu B.
        • Wang L.
        • Mao Y.
        • Zhou B.
        • Song Z.
        • et al.
        Anticoagulants is a risk factor for spontaneous rupture and hemorrhage of gallbladder: a case report and literature review.
        BMC Surg. 2019; 19: 2
        • Robertson F.M.
        • Crombleholme T.M.
        • Barlow S.E.
        • Verhave M.
        • Brown D.
        Ceftriaxone choledocholithiasis.
        Pediatrics. 1996; 98: 133-135
        • Kutuya N.
        • Ozaki Y.
        • Okazaki T.
        A symptomatic child with ceftriaxone-associated biliary pseudolithiasis.
        J Med Ultrason. 2008; 35 (2001): 125-128
        • Biner B.
        • Oner N.
        • Celtik C.
        • Bostancioğlu M.
        • Tunçbilek N.
        • Güzel A.
        • et al.
        Ceftriaxone-associated biliary pseudolithiasis in children.
        J Clin Ultrasound : JCU (J Clin Ultrasound). 2006; 34: 217-222
        • Alušík Š.
        • Paluch Z.
        Drug-induced Cholelithiasis.
        Curr Rev Clin Exp Pharmacol. 2021; 16: 300-305
        • Liang C.C.
        • Wang I.K.
        • Kuo H.L.
        • Yeh H.C.
        • Lin H.H.
        • Liu Y.L.
        • et al.
        Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.
        Ren Fail. 2011; 33: 489-493
        • Yoshida R.
        • Yoshizako T.
        • Katsube T.
        • Kitagaki H.
        Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults.
        Jpn J Radiol. 2019; 37: 826-831
        • Imafuku A.
        • Sawa N.
        • Sekine A.
        • Kawada M.
        • Hiramatsu R.
        • Yamanouchi M.
        • et al.
        Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.
        Clin Exp Nephrol. 2018; 22: 613-619
        • Hotta K.
        • Hashimura N.
        • Takatsuka M.
        • Matsuyama T.
        • Nakagawa K.
        • Yabusako T.
        • et al.
        Ceftriaxone-associated pseudolithiasis in elderly people: frequency and risk factors.
        Intern Med. 2021; 60: 3857-3864
        • Murata S.
        • Aomatsu T.
        • Yoden A.
        • Tamai H.
        Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis.
        Pediatr Int : official journal of the Japan Pediatric Society. 2015; 57: 942-946
        • Cohen D.
        • Appel G.B.
        • Scully B.
        • Neu H.C.
        Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.
        Antimicrob Agents Chemother. 1983; 24: 529-532
        • Ardu M.
        • Alemanno G.
        • Prosperi P.
        • Tucci R.
        • Iacopini V.
        • Frezzetti G.
        • et al.
        Hemoperitoneum from hemorrhagic perforated cholecystitis in a patient with acquired deficiency of factor VIII.
        Am Surg. 2020; 86: e191-e193
        • Shimura T.
        • Kojima T.
        • Tsutsumi S.
        • Yoshida T.
        • Uchiumi H.
        • Kuwano H.
        Gallbladder hematoma in a patient with hemophilia B, report of a case.
        Hepato-Gastroenterology. 2000; 47: 939-941